Hepatocellular Carcinoma Clinical Trial
Official title:
A Prospective Multicenter Cohort Control Study of Percutaneous Microwave Ablation and Laparoscopic Resection for Hepatocellular Carcinoma With a Diameter of 3.1 ~ 5.0cm
The study was a prospective multicenter cohort control study, which was divided into 1:1 groups to compare the clinical efficacy of percutaneous microwave ablation and laparoscopic hepatocellular carcinoma resection (tumor diameter 3.1-5.0cm).
Research objectives:
To compare the clinical efficacy of percutaneous microwave ablation and laparoscopic
resection for hepatocellular carcinoma (tumor diameter 3.1-5.0cm).
Research background:
Liver cancer is the sixth most common tumor in the world and the second leading cause of
death. Due to the hepatitis B epidemic, the incidence of liver cancer in China is very high,
accounting for about half of the global statistics on the number of new liver cancer cases
and deaths each year. Current treatment guidelines recommend surgical resection or
transplantation as the gold standard for the treatment of very early or early HCC patients.
Meanwhile, local ablation is gradually accepted by clinicians for its minimally invasive
nature, safety and efficacy, and it is recommended as an alternative treatment for tumors
within 3cm. However, the choice of treatment for 3.1-5cm HCC based on a number of current
retrospective studies is controversial. Therefore, we designed this study to provide reliable
prospective data to support the selection of therapeutic modalities for HCC.
Technical introduction:
Microwave ablation (MWA) is an ultrasound guided ablation electrode implanted in the target
tissue, in the form of electromagnetic waves to generate microwave energy, microwave can make
the surrounding tissue in the water molecules oscillate against the friction of heat, high
temperature heat causes rapid coagulation necrosis of the tissue, so as to achieve the
purpose of local tumor treatment. Compared with other ablation techniques, MWA in the
treatment of solid tumors can achieve higher tumor internal temperature in a shorter period
of time, with strong penetration, synergistic effect of multi-needle combined ablation, and
little influence by carbonization and blood perfusion. Therefore, MWA has fast heat
production, high intracellular temperature, short ablation time and large ablation range.
Laparoscopic liver resection (Laparoscopic hepatectomy) reported for the first time in 1991
by the professor Reich. Laparoscopic techniques in the application in benign (malignant)
liver disease is widespread. In China, since professor Weiping Zhou and others completed the
first laparoscopic liver resection in mainland China in 1994, there have been continuous
literature reports, and the scope and difficulty of surgical resection have been
increasing.The 2008 Louisville declaration states that laparoscopic liver surgery is safe and
effective for surgeons with extensive experience in hepatobiliary surgery and laparoscopic
surgery.
Research methods In this study, 1134 patients were expected to be enrolled according to the
1:1 grouping of the experimental group and the control group. The efficacy of the two
treatment methods was evaluated by comparing the overall survival of the two groups and other
indicators.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |